Glucagon-like peptide 1 (7-36)amide clinical trials
How each study uses glucagon-like peptide 1 (7-36)amide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the glucagon-like peptide 1 (7-36)amide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2007 (1)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2015 | 1 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 3
Mannkind Corporation (2) · Papworth Hospital NHS Foundation Trust (1) · Stanford University (1) · Dr Adnan Agha (1)
Often tested with
Tested in the same studies.
Beinaglutide (2) · Metformin (1) · Gastric Inhibitory Polypeptide (1) · Semaglutide (1) · Tirzepatide (1)
Studies
Open first, then newest update. How each study uses glucagon-like peptide 1 (7-36)amide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted PreventionNot yet recruitingPhase 4Stanford UniversityNCT06682351Written as GLP-1AHow we know
- Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 AnalogueRecruitingPhase 1/2Dr Adnan AghaNCT05751720Written as GIP/GLP-1aHow we know
- Human Vasodilatory Effect of GLP-1CompletedNot applicablePapworth Hospital NHS Foundation TrustNCT03502083Written as GLP-1 (7-36)AmideHow we know
- A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes MellitusCompletedPhase 1Mannkind CorporationNCT00642538Written as MKC253 Inhalation PowderHow we know
- A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult MalesCompletedPhase 1Mannkind CorporationNCT00475371Written as MKC253 Inhalation PowderHow we know